Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788080 · ClinicalTrials.gov registry record · Early Phase 1
Optimization of Biotinylation Protocol for Studies of Red Blood Cell Survival and Function After Transfusion
A Early Phase 1 study, sponsored by Vitalant Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT06788080 is a Early Phase 1 study that has completed, run by Vitalant Research Institute. The registered enrollment target is 12 participants.
The verdict
NCT06788080, a Early Phase 1 study, has completed, sponsored by Vitalant Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to compare two methods of labeling red blood cells with biotin. The main question to answer is whether red blood cells labeled 48 hours before transfusion survive as long as red blood cells labeled 6 hours before transfusion. Secondary questions are to measure the quality of the red blood cells and whether or not the biotin-labeled red blood cells induce antibodies in transfusion recipients. This study participant will have six study visits: 1. Screening visit, collect 35 ml blood, about 3 tablespoons 2. Donate 500 ml blood 3. Receive 20 ml of biotin labeled blood transfusion, collect 40 ml blood, about 3 tablespoons 4. Return 1 day after transfusion for blood draw (25 ml, about 2 tablespoons) 5. Return 30 days after transfusion for blood draw (25 ml, about 2 tablespoons) 6. Return 90 days after transfusion for blood draw (25 ml, about 2 tablespoons)
Interventions
- DRUG BioRBC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-03-07 |
| Est. Completion | 2024-11-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06788080
The ClinicalTrials.gov registry entry for NCT06788080 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vitalant Research Institute, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BioRBC is the first listed.
NCT06788080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06788080 about?
NCT06788080 is a clinical study titled "Optimization of Biotinylation Protocol for Studies of Red Blood Cell Survival and Function After Transfusion". The goal of this clinical trial is to compare two methods of labeling red blood cells with biotin. The main question to answer is whether red blood cells labeled 48 hours before transfusion survive as long as red blood cells labeled 6 hours before transfusion. Secondary questions are to measure the ...
What is the current status of trial NCT06788080?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2024-03-07. Estimated completion is 2024-11-04.
What interventions are being tested in trial NCT06788080?
The interventions under investigation include: BioRBC (DRUG).
Who is sponsoring clinical trial NCT06788080?
This trial is sponsored by Vitalant Research Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.